Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab in relapsed/refractory pediatric mature B-cell non-Hodgkin lymphoma
2023-504264-41-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Nov 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, open-label trial of glofitamab in mature B-cell lymphoma, Burkitt lymphoma (BL), Burkitt leukemia and 2 more (2 cohorts), sponsored by Roche. Primary endpoints: Complete response rate, Adverse events and 3 more. Planned start Nov 2022; status: authorised.
02
Drugs
glofitamab
03
Conditions
mature B-cell lymphomaBurkitt lymphoma (BL)Burkitt leukemiadiffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on 2023-504264-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504264-41-00.